Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib

Herz

Volumn 38, Issue 8, 2013, Pages 931-933

  Kim, J C ^a   Shin, S H ^a   Yi, H G ^a   Kim, S H ^a   Woo, S I ^a   Kim, D H ^a   Park, K S ^a   Kwan, J ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARAGINASE; CREATINE KINASE; CREATINE KINASE MB; D DIMER; DASATINIB; DAUNORUBICIN; IMATINIB; PREDNISOLONE; TROPONIN I; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; INDUCTION CHEMOTHERAPY; LUNG ARTERY PRESSURE; LUNG CONGESTION; MALE; NAUSEA; PLEURA EFFUSION; PULMONARY HYPERTENSION; SYSTOLIC HEART MURMUR; T WAVE INVERSION; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION; VOMITING; YOUNG ADULT;

ADULT; HUMANS; HYPERTENSION, PULMONARY; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 84891273474     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-013-3765-7     Document Type: Article

References (10)

1. Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270
2. Fielding AK (2011) Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2011:231-237
3. Bergeron A, Rea D, Levy V et al (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 176:814-818
4. Montani D, Bergot E, Günther S et al (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125:2128-2137
5. Orlandi EM, Rocca B, Pazzano AS, Ghio S (2012) Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 36:e4-e6
6. Dumitrescu D, Seck C, ten Freyhaus H et al (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 38:218-220
7. Rasheed W, Flaim B, Seymour JF (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33:861-864
8. Hennigs JK, Keller G, Baumann HJ et al (2011) Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11:30
9. Schermuly RT, Dony E, Ghofrani HA et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811-2821
10. Pullamsetti SS, Berghausen EM, Dabral S et al (2012) Role of SRC tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 32:1354-1365